Market Access News | pharmaphorum

News

Roche gets first world okay for PNH drug crovalimab

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal ha

News

Vertex’s chief executive Reshma Kewalramani

Vertex seeks swift review of new CF triple after ph3 readout

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit

News

FDA sets date for Adaptimmune’s sarcoma drug verdict

The FDA is due to decide by 4th August whether to approve Adaptimmune’s engineered T-cell therapy for advanced synovial sarcoma, afamitresgene autoleucel (afami-cel), afte

News

Global cancer burden study reveals ‘striking inequity’

The World Health Organization (WHO) has said that the burden of cancer on societies around the world is growing at an alarming rate, with a 77% increase in new cases expec

News

AbbVie’s Tepkinly backed by NICE for DLBCL patients

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an

News

FDA starts swift review of tumour-agnostic use of Enhertu

AstraZeneca and Daiichi Sankyo’s Enhertu could become the first therapy approved by the FDA for use in any HER2-positive cancer, regardless of its location in the body.

Roche gets first world okay for PNH drug crovalimab

Vertex seeks swift review of new CF triple after ph3 readout

FDA sets date for Adaptimmune’s sarcoma drug verdict

Global cancer burden study reveals ‘striking inequity’

AbbVie’s Tepkinly backed by NICE for DLBCL patients

FDA starts swift review of tumour-agnostic use of Enhertu

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks